…and some to sell

4d Pharma Investors Chronicle

The biotech firm, which focuses on treatments for IBS, is suffering slow progress in a market already crammed with over-the-counter medicines. Given such an unpromising pipeline, the £200m market cap seems heady. Sell. 323p.

Barclays Sharecast

Goldman Sachs worries that Barclays’ need to build capital could allow competitors to capture revenue growth. Regulatory hurdles may also be a hindrance. Analysts have slashed the target price by 28% to 180p. Sell. 208p.

Burberry Group Sharecast

RBC Capital Markets expects another year of pedestrian sales and below-sector earnings growth from the fashion group. With limited scope for cost savings, profit forecasts have been downgraded. Sell. £15.94.

Indivior The Times

Indivior has been a “startling performer” since its 2014 demerger from Reckitt Benckiser: shares are up 130%. Yet uncertainties remain. The firm is worryingly dependent on just one drug – the opioid addiction treatment, Suboxone. Sell. 326p.

Inmarsat Sharecast

While conceding that the satellite telecoms firm is “well set for recovery”, Barclays has downgraded it to “underweight”. There are worries about medium-term demand, given increased supply and looming “technological obsolescence”. Sell. 750p.

N Brown Investors Chronicle

The clothing retailer’s betterthan-expected figures and new partnership with Tesco are laudible in a tough market. But downward pressure on margins will continue, despite the relief rally on results. Sell. 239p.